Roche Holding (ROP) Aandelenoverzicht

Roche Holding AG houdt zich bezig met farmaceutica en diagnostica in Europa, Noord-Amerika, Latijns-Amerika, Azië, Afrika, Australië en Nieuw-Zeeland. Meer informatie

ROP fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	2/6
Prestaties in het verleden	4/6
Financiële gezondheid	4/6
Dividenden	5/6

Beloningen

Verhandeld tegen 60% onder onze schatting van de reële waarde

De winst zal naar verwachting met 10.02% per jaar groeien

Betaalt een betrouwbaar dividend van 2.75%

Risicoanalyse

Heeft een hoog schuldenniveau

ROP Community Fair Values

Create Narrative

See what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

3.6% ondergewaardeerd

AnalystConsensusTarget

1mo ago

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

191

33.2% overgewaardeerd

AnalystLowTarget

27d ago

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

16.6% ondergewaardeerd

AnalystHighTarget

5mo ago

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche Holding

Eerlijk gewaardeerd

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

kapirey

Published 12 May

Read Narrative

Top Community Narratives

Roche Holding

Eerlijk gewaardeerd

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

kapirey

Published 12 May

Read Narrative

Top Analyst Narratives

3.6% ondergewaardeerd

AnalystConsensusTarget

1mo ago

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

191

33.2% overgewaardeerd

AnalystLowTarget

27d ago

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

16.6% ondergewaardeerd

AnalystHighTarget

5mo ago

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

View all narratives

Roche Holding AG Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Roche Holding
Historische aandelenkoersen
Huidige aandelenkoers	CHF 356.80
52 Week Hoogtepunt	CHF 375.80
52 Week Laag	CHF 252.20
Bèta	0.35
1 maand verandering	-5.01%
3 maanden verandering	11.99%
1 Jaar Verandering	34.59%
3 jaar verandering	43.06%
5 jaar verandering	4.82%
Verandering sinds IPO	1,267.05%

Recent nieuws en updates

Recent updates

Narratiefupdate • Aug 24

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Analysts have nudged their fair value estimate for Roche Holding to CHF 267.89 from CHF 260.11, citing a mix of higher assumed revenue growth, a slightly adjusted discount rate, modestly lower profit margin expectations, and a marginally higher future P/E. Analyst Commentary Recent Street research around Roche Holding offers a mixed picture for investors, with some firms highlighting potential growth drivers while others flag valuation and execution risks.

Narratiefupdate • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Analysts have lifted their fair value estimate for Roche Holding to CHF 370.31 from CHF 359.22, citing a combination of visible growth, incremental pipeline contributions including giredestrant, and recent partnership activity. They view these factors as supporting revenue growth assumptions and profit margin resilience, despite a slightly higher discount rate and a modestly lower future P/E multiple.

Analyse-artikel • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

Narratiefupdate • Jul 27

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analysts lifted their fair value estimate for Roche Holding, implying a new price target of about CHF 260. They incorporated updated assumptions on revenue growth, margins and P/E following a series of partnership-focused research notes around the company's Nurix collaboration and a recent HSBC rating change.

Analyse-artikel • Jul 27

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Investors in Roche Holding AG ( VTX:ROP ) had a good week, as its shares rose 7.1% to close at CHF355 following the...

Narratiefupdate • Jul 10

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Analysts have modestly lifted their fair value estimate for Roche Holding to CHF 359.22 from CHF 352.00, citing updated assumptions around revenue growth, profit margins and future P/E, along with mixed but generally constructive readthroughs from recent pipeline and partnership research. Analyst Commentary Recent Street research around Roche Holding points to a mixed but constructive setup, with optimism around specific products and partnerships balanced by more cautious views on the risk and timing of future growth and execution.

Narratiefupdate • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.

Nieuw narratief • May 12

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Investment Memo – Roche Holding AG (Pharmaceutical Division / “Roche Pharma”) 1. Executive Summary Roche is a leading global pharmaceutical and diagnostics company with a strong focus on oncology, immunology, neuroscience, and rare diseases.

Nieuw narratief • Apr 19

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?

Nieuw narratief • Apr 04

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?

Nieuw narratief • Mar 21

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?

Rendement voor aandeelhouders

	ROP	CH Pharmaceuticals	CH Markt
7D	3.7%	3.1%	0.2%
1Y	34.6%	25.8%	12.2%

Rendement versus industrie: ROP overtrof de Swiss Pharmaceuticals industrie, die het afgelopen jaar een rendement 25.8 % opleverde.

Rendement versus markt: ROP overtrof de Swiss markt, die het afgelopen jaar een rendement opleverde van 12.2 %.

Prijsvolatiliteit

Is ROP's price volatile compared to industry and market?
ROP volatility
ROP Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	4.4%
Market Average Movement	3.9%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

Stabiele aandelenkoers: ROP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Swiss markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van ROP is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG houdt zich bezig met farmaceutica en diagnostiek in Europa, Noord-Amerika, Latijns-Amerika, Azië, Afrika, Australië en Nieuw-Zeeland. Het bedrijf biedt farmaceutische oplossingen op het gebied van bloedarmoede, bloed- en solide tumoren, dermatologie, hematologie, infectieziekten, ontstekings- en auto-immuunziekten, neurologische aandoeningen, oogheelkunde, ademhalingsaandoeningen en transplantatie. Het bedrijf levert ook in-vitrotests voor de diagnose van verschillende ziekten, zoals kanker, diabetes, Covid-19, hepatitis, humaan papillomavirus en andere; diagnostische instrumenten; en digitale gezondheidsoplossingen.

Roche Holding AG Samenvatting

Hoe verhouden de winst en inkomsten van Roche Holding zich tot de beurswaarde?
ROP fundamentele statistieken
Marktkapitalisatie	CHF 285.14b
Inkomsten(TTM)	CHF 12.34b
Inkomsten(TTM)	CHF 62.96b

23.0x

Koers/Winstverhouding

4.5x

P/S-verhouding

Is ROP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ROP resultatenrekening (TTM)
Inkomsten	CHF 62.96b
Kosten van inkomsten	CHF 16.26b
Brutowinst	CHF 46.70b
Overige uitgaven	CHF 34.35b
Inkomsten	CHF 12.34b

Laatst gerapporteerde inkomsten

Jun 30, 2026

Volgende inkomensdatum

Oct 22, 2026

Winst per aandeel (EPS)	15.49
Brutomarge	74.17%
Nettowinstmarge	19.60%
Schuld/Eigen Vermogen Verhouding	86.6%

Hoe presteerde ROP op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.7%

Huidig dividendrendement

63%

Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/09/20 23:32
Aandelenkoers aan het einde van de dag	2026/09/18 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Roche Holding AG wordt gevolgd door 45 analisten. 19 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding (ROP) Aandelenoverzicht

Beloningen

Risicoanalyse

Analyst Price Targets

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Analyst Narratives

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Holding AG Concurrenten

Novartis

Galderma Group

Sandoz Group

Dottikon ES Holding

Prijsgeschiedenis en prestaties

Recent nieuws en updates

CHMP Backs EU Approval of Roche Ocrevus for Paediatric Multiple Sclerosis Patients

Roche Reports Positive Phase III Results for Lunsumio and Lenalidomide in Lymphoma

Roche Receives Chmp Recommendation for Ocrevus Approval in Paediatric Relapsing Multiple Sclerosis

Roche Reports Phase III Celestimo Study Results for Lunsumio-Based Regimen in Follicular Lymphoma

Roche Advances Global Plans After Tam-Peli Lung Cancer Trial Shows Survival Benefit

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Recent updates

CHMP Backs EU Approval of Roche Ocrevus for Paediatric Multiple Sclerosis Patients

Roche Reports Positive Phase III Results for Lunsumio and Lenalidomide in Lymphoma

Roche Receives Chmp Recommendation for Ocrevus Approval in Paediatric Relapsing Multiple Sclerosis

Roche Reports Phase III Celestimo Study Results for Lunsumio-Based Regimen in Follicular Lymphoma

Roche Advances Global Plans After Tam-Peli Lung Cancer Trial Shows Survival Benefit

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Roche Receives FDA Approval For Companion Diagnostic Tests to Identify Patients With HER2-Positive Metastatic Gastroesophageal Adenocarcinoma Eligible For ZIIHERA

Roche Licenses Hanmi Obesity Drug Candidate in $2.3 Billion Deal With Genentech

Roche Receives FDA Clearance For Elecsys Ptau217 Blood Test For Alzheimer’s Disease Assessment

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Roche Gains FDA Clearance for cobas BV/CV Molecular Vaginitis Diagnostic

First half 2026 earnings released

CHMP Backs EU Approval for Susvimo Continuous Eye Treatment in Roche Milestone

Roche Receives Positive CHMP Recommendation For Susvimo For Neovascular Age-Related Macular Degeneration

Roche Receives FDA Clearance For The Cobas BV/CV Assay Enabling Fast And Highly Accurate Vaginitis Diagnosis

Roche Names Dan Malarek CEO of Diagnostics North America as Leadership Team Shifts

FDA Sets Priority Review for Roche’s Gazyva in Rare Kidney Disease Therapy Decision

Roche Announces FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy

Roche Unveils First Fully Automated HDV Test for Severe Hepatitis Detection and Monitoring

Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Roche Receives CE Mark for Automated Tuberculosis Blood Test Across Europe

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer

FDA Accepts Priority Review for Roche Enspryng in Thyroid Eye Disease Expansion

Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease

Roche Announces Launch Of AXELIOS 1 Sequencing Platform

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Roche Backs Orano Med to Advance Lead-212 Radiopharma Cancer Therapies

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer

Roche Expands Cancer Diagnostics and Awaits FDA Decision on Tecentriq for Colon Cancer

Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer

Roche Advances Breast Cancer Pipeline With FDA Review for Giredestrant and Companion Diagnostic Approval

Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer

Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi (Inavolisib) in Combination with Palbociclib and Fulvestrant

Roche Launches the Liver Disease Panel Suite of Certified Algorithms to Support Chronic Liver Disease Management

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Roche Receives CE Mark For Elecsys Ptau217 Blood Test For Alzheimer’S Disease Pathology